CHONDROTOXICITY OF FLUOROQUINOLONES IN CHILDREN: YES OR NO?

Two groups of children on therapy with monofluoroquinolones were enrolled in this open research trial: 169 patients with cystic fibrosis (exacerbation period) and 55 patients with aplastic anemia (neutropenic phase); age was from 6 months to 16 years. The aim of the study was to compare tolerability (with the focus on arthrotoxicity) of ciprofloxacin, ofloxacin and pefloxacin during intermittent (15-50 mg/kg/day in cystic fibrosis patients) and prolonged continuous therapy (10-15 mg/kg/day in patients with aplastic anemia). Quinolone-induced arthropathy was reported in 7, 6% of all cases, mainly during pefloxacin therapy (31, 8%), and more frequently in patients with aplastic anemia (10, 9% vs. 7, 7%), only in pubertal children, and was fully reversible with no influens on the lineal growth. Following the monofluoroquinolones use, residual joint-related symptoms were not observed because monofluoroquinolones did not achieve chondrotoxic concentrations in cartilaginous structures.

дети, муковисцидоз, апластическая анемия, монофторхинолоны, артротоксичность, линейный рост, морфология хряща, кумуляция фторхинолонов, children, cystic fibrosis, aplastic avemia, monofluoroquinolones, arthrotoxicity, linear growth, chondral morphology, fluoroquinolones accumulation

1. И.К. Волков, Л.К. Катосова, И.В. Давидов, Л.П. Клюкина. «Эффективность фторхинолона левофлоксацина при хронических заболеваниях легких у детей». Фторхинолоны в педиатрии: Сб. статей. М. Вузовская книга, 2005, 76с.

2. Schaad U. Use of the quinolones in pediatrics. In: The quinolones. New York. Academic press.

3. Schaad U. Use of the quinolones in pediatrics. Jsr J Med Sci 1994; 30-463-9.

4. Schaad U. Toxicity of quinolones in pediatric patients. Adv Antimicrob Antineopl Chemother 1992; 11: 259-65.

5. Schaad U. Use of the quinolones in pediatrics. Drugs 1993; 45: 37-41.

6. Schmidt M., Hoffmann K. The use quinolones in children - toxicological aspects. Adv Antimicrob Antineopl Chemother.

7. Stahlmann R., Foster C., Sickle D., Quinolones in children: are concerns over arthopathy justifield? Drug Safety 1993; 6: 397-403.

8. Wilcox M. A question of toxicity: antimicrobial development - the Libra approach. Antibiot Chemother 1999; 3: 6-16.

9. Goodman L., Gilman A. Fluoride. In: The pharmacological basic of therapeutics. New York: MacMillan Publishing Company; 1985.

10. Dequeker I., Dequeker K., Fluor in the treatment of osteoporosis. An over view of thirty years clinical research. Schweiz Med Wochenschr 1993; 27: 2228-34.

11. Whitford G. Acute and chronic fluoride toxicity. J of Dental Research 1992; 71: 1538: -40.

12. Shahlmann R., Lode H., Safety overview (toxicity, adverse effect and drug interactions). In: The quinolones. New York. Academic press; 1998.

13. Schluter G. Toxicology of ciprofloxacin. In: Internat Ciproflox Workshop Exerpa Medica; 1986: 61-7.

14. Авцын А.П., Жаворонков А.А. патология флюороза. Новосибирск: Наука; 1981.

15. Авцын А.П., Жаворонков А.А., Строчкова Л.С. Микроэлементозы человека. М.: Медицина; 1991.

16. Белобородова Н.В., Падейская Е.Н., Бирюков А.В. Фторхинолоны в педиатрии - за и против. Педиатрия 1996; 2: 79-84.

17. Родин В.А., Фролова Г.И., Пинелис Т.П. Геохимическая характеристика Читинской области по содержанию фтора в почвенной воде. Тр Читинского Гос Мед Ин-та 1990: 133-4.

18. Семыкинн С.Ю. Эффективность и безопасность применения ципрофлоксацина при лечении бронхолегочного процесса у детей с муковисцидозом. Автореф. дис.. канд. мед. наук. М.: 2002.

19. Урбах В.Ю. Статистический анализ в биологических и медицинских исследованиях. М.: 2002.